A compound that reached real human trials and returned mixed results, which is more informative than never having been tested

Under its development name this molecule progressed to registered human studies for mitochondrial conditions.

It reached clinical trials, which most items here did not

Under its development name this molecule progressed to registered human studies for mitochondrial conditions. That alone separates it from most of this index.

The results were mixed, and that is the useful part

Trials have produced inconsistent outcomes, with some endpoints missed. A compound with published disappointing results is better documented than one with no results at all, and informal summaries tend to cite the encouraging studies while omitting the rest.

Mitochondrial endpoints are hard to measure

Trials in this area struggle with endpoint selection — what to measure, over what period, in a small and heterogeneous patient group. Some inconsistency reflects the difficulty of measurement rather than absence of effect, and distinguishing the two is genuinely unresolved.

Trial populations were specific

Participants had defined conditions. Results from that setting say little about healthy use, and the trials were not designed to.

The honest summary

Genuinely trialled in humans, results mixed, measurement contested. That is a more complete evidence picture than most compounds here have, and it is less flattering than the summaries that cite only the positive studies.

The published record for this item

The published set we counted contains 4 report(s) naming SS-31, averaging 99.82% purity. Each resolves on the testing laboratory's own portal rather than as a file hosted by the seller.

Why mixed results are more informative than none

A compound with published disappointing trials is better characterised than one with no human data at all. Informal summaries tend to cite the encouraging studies and omit the rest, which inverts the usual relationship between how much is known and how confident a claim sounds.

Endpoint selection drives the disagreement

Where trials in an area disagree, the cause is often that they measured different things over different periods. Comparing the endpoints before comparing the conclusions resolves a large share of apparent contradictions in this literature.

Check for a registry entry

Trials registered before enrolment can be compared against what was eventually published, and a registered endpoint that disappears from the paper is a documented pattern worth looking for. An unregistered trial cannot be checked this way at all.

Where to check this independently

The claims on this page about a compound that reached real human trials and returned mixed results, which is more informative than never having been tested can be checked against sources outside this site:

The code is HEALTHYLIFE10, worth 10% off the subtotal sitewide at growthguys.com. It carries no minimum and no exclusions, and every test of it is dated and published — the evidence index, and the full code page.

Related